CAPTRUST Financial Advisors
MRTX

CAPTRUST Financial Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-840
Closed -$56K – 4349
2022
Q2 		$56K Sell
840
-137
-14% -$8.71K ﹤0.01% 2661
2022
Q1 		$80K Buy
977
+917
+1,528% +$93.8K ﹤0.01% 2447
2021
Q4 		$9K Sell
60
-40
-40% -$6.21K ﹤0.01% 3806
2021
Q3 		$18K Buy
100
+57
+133% +$9.17K ﹤0.01% 3246
2021
Q2 		$7K Sell
43
-15
-26% -$2.41K ﹤0.01% 3731
2021
Q1 		$10K Buy
58
+8
+16% +$1.58K ﹤0.01% 3455
2020
Q4 		$11K Buy
+50
New +$10.8K ﹤0.01% 2539

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

CAPTRUST Financial Advisors's MRTX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2022, closing a stake of 840 shares — an estimated $56K sold.

CAPTRUST Financial Advisors first reported a position in MRTX in Q4 2020 and held it in 7 quarters. The position peaked at $80K in Q1 2022. 243 funds tracked by Wall St. Rank hold MRTX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 840 Mirati Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $56K.
  • CAPTRUST Financial Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • CAPTRUST Financial Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $80K in Q1 2022.
  • 243 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.